You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
再鼎醫藥(09688.HK):2023年全年產品收入為2.667億美元

格隆匯2月28日丨再鼎醫藥(09688.HK)公佈2023年全年財務業績,2023年全年產品收入為2.667億美元,2022年同期為2.127億美元,同比增長25%,按固定匯率計算同比增長31%。衞偉迦®(艾加莫德α注射液)於2023年9月在中國上市,據估算其在被納入國家醫保藥品目錄(NRDL)前已治療近1000名患者。僅2024年1月,據估算近1000名患者接受衞偉迦的治療;預計2024年衞偉迦的產品銷售額將超過7000萬美元。

再鼎醫藥創始人、董事長兼首席執行官杜瑩博士表示:“2023年,我們圍繞多個關鍵戰略重點取得了出色進展,尤其是衞偉迦9月在中國商業化上市用於全身型重症肌無力(gMG),併成功被納入國家醫保藥品目錄。衞偉迦的上市展現出良好的開端,今年1月的患者數量就超過了2023年最後四個月的患者總和,這得益於醫生的高度認可和衞偉迦加速進院,患者可及性得到提高。展望未來,我們預計今年再鼎將繼續保持強勁的商業化表現,同時我們還在為有望於今年獲批的三款創新藥做好上市準備。我們也對後期管線的研發進展和不斷壯大的全球早期開發工作感到興奮。再鼎將在實現五年戰略計劃目標的道路上行穩致遠,不斷成長為一家高增長、能盈利和有創新的生物醫藥公司。”

再鼎醫藥總裁兼首席運營官Josh Smiley表示:“我們致力於實現三大企業發展目標。首先,我們將在未來兩到三年內上市多個新產品和新適應證,加速營收增長。其次,我們的目標是通過收入增長、持續關注效率和生產力提升,到2025年底實現公司盈利。最後,我們致力於通過內部開發和戰略性商務拓展來加強我們的全球管線組合。這些公司目標體現了再鼎醫藥的願景,我們將引領創新,明確目標,達成增長,以實現改善全球患者生活的願景。”

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account